Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

SNSS $0.65 0.1439 +28.44%
CYTK $11.12 1.1700 +11.76%
SPHS $5.86 0.4600 +8.52%
BDSI $2.55 0.2000 +8.51%
NKTR $17.29 1.1900 +7.39%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

PVCT $0.29 -0.0200 -6.45%
TGTX $5.91 -0.4000 -6.34%
VSTM $1.40 -0.0800 -5.41%
GALE $0.44 -0.0254 -5.40%
NLNK $10.58 -0.5300 -4.77%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Next > | Last >>

Lung Cancer Breakthrough? Chinese Scientists' Gene-Editing Technique CRISPR Approved For Testing

(IBTimes) July 21, 2016 - In an attempt to treat lung cancer, a group of Chinese scientists is set to be the first in the world to inject patients with immune cells modified with a specific gene-editing technique, according to an exclusive report by Nature.
read article 



'Survival of the Nastiest': New Approach Seeks To Stop Drug-Resistant Cancer Evolving

(The Telegraph/Press Association [UK]) July 22, 2016 - A revolutionary approach to tackling cancer that targets the way tumours evolve and become resistant to drugs is to be tested for the first time in the world in the UK.
read article 



Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III Trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)

(Puma Biotechnology) July 21, 2016 - Puma Biotechnology, Inc., a biopharmaceutical company, announced updated results from the Phase III clinical trial of Puma's investigational drug PB272 (neratinib) for the extended adjuvant treatment of HER2-positive early stage breast cancer (ExteNET trial).
read corporate press release 



For Surgeons, Talking About Adverse Events Can Be Difficult: Study

(Kaiser Health News) July 20, 2016 - Research suggests surgeons might be better off if they learn to quickly and directly explain what went wrong to the patient.
read article 



Biogen CEO Resigns After Six Years of Boom-and-Bust Leadership

(TheStreet.com) July 21, 2016 - The departure of Biogen's CEO could lead to a sale of the biotech company, or a renewed push to boost its own M&A activities.
read article 



Generic Crestor Wins Approval, Dealing a Blow to AstraZeneca

(New York Times) July 20, 2016 - The Food and Drug Administration said Wednesday that it had approved generic versions of the blockbuster cholesterol-lowering pill Crestor, rejecting a last-ditch and controversial effort by AstraZeneca to stop cheaper competition from reaching pharmacy shelves.
read article 



Researchers Just Doubled What We Know About the Map of the Human Brain

(Washington Post/Speaking of Science) July 20, 2016 - Scientists like to say the human brain is the most complex object in the universe — three pounds of fluid and tissue, about which we understand only a fraction.
read article (free registration required) 



Congressman Mark Takai Dies 9 Months After Cancer Diagnosis

(STAT) July 20, 2016 - In January, Mark Takai, a first-term congressman from Hawaii who was fighting pancreatic cancer, made national headlines when he embraced Vice President Joe Biden at a Democratic retreat — and gave an emotional endorsement to the vice president’s cancer research initiative.
read article 



Navigating Cancer As A Trans Person Is A Nightmare

(Newsweek) July 21, 2016 - Discomfort—or blatant discrimination—on the part of doctors and nurses is just one of a host of factors that make catching and treating cancer a challenge in the trans population.
read article 



The 'Quantum Theory' of Cancer Treatment

(PBS/Nova Next) July 20, 2016 - There are now dozens of clinical trials combining radiation with a range of immunotherapies, including cancer vaccines and oncolytic viruses.
read article 



St. Baldrick's Foundation Grants More Than $22 Million For Lifesaving Childhood Cancer Research

(St. Baldrick's) July 21, 2016 - The St. Baldrick's Foundation, a volunteer-powered charity dedicated to raising money for childhood cancer research, is proud to announce that it has awarded 79 new grants totaling more than $22 million to support the best and brightest researchers looking for cures and better treatments for all childhood cancers.
read press release 



Viewpoint: Medicare Part B Reform A Victory For Cancer, Not Patients

(Florida Sun-Sentinel) July 20, 2016 - Every day, more than 300 Floridians are diagnosed with cancer. These patients will face enormous obstacles while battling their diseases. And their struggle is about to get considerably more difficult.
read article 



Cancer ‘Moonshot' Changes to Benefit All Disease Research

(Bloomberg BNA) July 19, 2016 - The White House's cancer “moonshot” initiative will benefit research across disease groups as changes implemented address systemic issues that hamper research progress, a White House aide said July 19.
read article 



Advaxis’ AXAL Receives Fast Track Designation by the FDA as Adjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Patients

(Yahoo! Finance) July 21, 2016 - Advaxis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the Company’s lead immunotherapy candidate, axalimogene filolisbac (AXAL), as a Fast Track product for adjuvant therapy for high-risk locally advanced cervical cancer patients.
read article 



Uncovering a New Principle In Chemotherapy Resistance In Breast Cancer

(NCI) July 20, 2016 - A laboratory study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
read press release 



Cancer-Fighting Bacteria

(MIT News) July 20, 2016 - Researchers at MIT and the University of California at San Diego (UCSD) have recruited some new soldiers in the fight against cancer — bacteria.
read article 



Precision Cancer Test Validated for Clinical Usage

(Weill Cornell) July 20, 2016 - A powerful next-generation genome-sequencing test developed at Weill Cornell Medicine can detect mutations that guide precision cancer treatment with over 95 percent accuracy, according to new research.
read press release 



New Drug Brings New Problem

(MedPage Today) July 20, 2016 - The multiple myeloma drug daratumumab (Darzalex) interferes with the standard procedure for testing blood compatibility prior to transfusions, researchers said, who raised the possibility that it is not alone in such effects.
read article (free registration required) 



High Polyp Rate Found in Cancer Survivors Treated With ART

(Medscape Medical News) July 21, 2016 - Cancer survivors previously treated with abdominal/pelvic radiation therapy (ART) are known to be at increased risk for colorectal cancer (CRC), but guidelines on early screening are inconsistent, in part because there has been no evidence that after treatment, CRC passes through a preclinical phase that is detectable through screening.
read article (free registration required) 



PSA Screening: Don't Throw the Baby Out With the Bathwater

(Medscape Medical News) July 21, 2016 - Two groups of experts agree that PSA testing can reduce prostate cancer deaths, but what type of screening strategy will work best?
read article (free registration required) 



Amgen, Allergan Biosimilar Found as Effective as Roche Cancer Drug

(Reuters) July 21, 2016 - Amgen Inc and Allergan Plc said their copycat version of Roche Holding AG's blockbuster cancer treatment, Herceptin, was found as effective as the original in a late-stage study.
read article 



Flawed Study of Advanced Prostate Cancer Spreads False Alarm

(New York Times) July 20, 2016 - Bad news for men popped up in news media all over the country this week, based on a study from Northwestern University reporting that cases of advanced, aggressive prostate cancer had risen sharply from 2004 to 2013.
read article 



Breakthrough Lung Cancer Drug Must Be Available On NHS, AstraZeneca Says

(The Telegraph [UK]) July 20, 2016 - A breakthrough lung cancer drug developed by UK scientists, which passed final clinical trials this week, might not be available on the NHS because it has been deemed too expensive by the drugs watchdog, it has emerged.
read article 



Pairing New Cancer Drugs With Older Ones Bolsters Roche Profit

(Bloomberg) July 21, 2016 - Roche Holding AG said combining tumor medicines for extra potency, a strategy that helped spur first-half earnings by reviving sales of older drugs like Herceptin, is the way of the future in cancer.
read article 



Medidata Collaborates with Leading New York Cancer Center to Expand the Use of mHealth Technology in Oncology Care

(4-traders) July 19, 2016 – Medidata, the leading global provider of cloud-based solutions for clinical research in life sciences, today announced it is collaborating with Memorial Sloan Kettering Cancer Center (MSK) to expand the use of mobile health (mHealth) technology in oncology treatment.
read article